Deciphera Pharmaceuticals $135.1 million common stock offering
The common stock is listed on the Nasdaq Global Select Market
Davis Polk advised the joint book-running managers in connection with a $135.1 million SEC-registered common stock offering by Deciphera Pharmaceuticals, Inc. The common stock is listed on the Nasdaq Global Select Market under the symbol “DCPH.”
Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. In addition to advancing multiple product candidates from its platform in clinical studies, QINLOCK is Deciphera’s switch control inhibitor for the treatment of fourth-line GIST.
The Davis Polk corporate team included partner Richard D. Truesdell Jr., counsel Jeffrey S. Ramsay and associate Xi (Brooke) Zheng. The tax team included counsel Tracy L. Matlock and associate Liang Zhang. The intellectual property and technology transactions team included partner David R. Bauer and associate Alison T. Chin. The environmental team included counsel David A. Zilberberg and associate Timothy J. Sullivan. All members of the Davis Polk team are based in the New York office.